Amedica, whose backers include GE Capital and Creation Capital, announced the pricing of its initial public offering of 3,500,000 shares of common stock at a public offering price of $5.75 per share. JMP Securities is acting as the sole bookrunning manager for the offering. Needham & Company is acting as co-manager for the offering.

In addition, Amedica has granted the underwriters a 30-day option to purchase up to an additional 525,000 shares of common stock from Amedica at the public offering price, less underwriting discounts. The offering is expected to close on February 19, 2014, subject to customary closing conditions. Amedica’s common stock has been approved for listing on the NASDAQ Capital Market and is expected to begin trading under the ticker symbol “AMDA” on February 13, 2014.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 12, 2014. The offering will be made only by means of a prospectus.

Amedica is a commercial biomaterial company focused on using its silicon nitride technology platform to develop, manufacture and sell a broad range of medical devices.